

MILAN, ITALY

# CareDx at ESOT 2021: Showcasing 6 AlloSeq cfDNA scientific posters/presentations



Patrick G., kidney transplant recipient

## ■ AlloSeq<sup>®</sup> cfDNA: The cutting edge solution to detect dd-cfDNA for transplant surveillance

Type	Title	Presenter	Session Date and Time
Focus group	Pitfalls in the detection of donor-derived cell-free DNA in transplant recipients	Dr Jeroen Verhoeven	Aug 30; 16:45 – 18:15
Focus group	Comparing methods for donor-derived cell-free DNA quantification in plasma and urine from kidney and liver transplant recipients	Dr Nicholas Kueng	Aug 30; 16:45 – 18:15
Oral Presentation #OP450	Monitoring kidney graft injury by measuring donor-derived cell-free DNA (dd-cfDNA)	Dr Emilio Rodrigo	Sept 1; 08.00 – 09.30
Oral Presentation #OP706	Prospective evaluation of donor-derived cell-free DNA (dd-cfDNA) in kidney transplant recipients with indication biopsy	Dr Louise Benning	Sept 1; 08.00 – 09.30
Oral Presentation #OP471	Diagnostic value of donor-derived cell-free DNA to predict antibody-mediated rejection in donor-specific antibody-positive renal allograft recipients	Dr Katharina Mayer	Sept 1; 10:00 – 11:30
Poster # POS754	Prospective assessment of graft recovery after kidney transplantation by means of donor-derived cell-free DNA	Dr David Cucchiari	E-poster

## CareDx is excited to partner with Cibiltech to drive Transplant Innovation

Cibiltech develops predictive digital solutions to monitor transplant patients. Predigraft, Cibiltech's first medical device, is a predictive algorithm for renal graft survival powered by the iBox. The iBox algorithms have been validated on a retrospective cohort of 4000 patients and have resulted in major publications in this field. The prediction of renal survival makes it possible to personalise and improve the therapeutic follow-up of patients. It is combined with a remote monitoring tool for transplant patients to improve the patients quality of life and reduce costs for healthcare systems.

The iBox is also available for clinical research purposes, as a digital biomarker for graft survival.

